Current explanations for this increased risk of VTE in patients with a malignant neoplastic process is that cancer cells synthesize and release procoagulants in the nearby tumor microenvironment; the main procoagulants implicated in cancer-associated VTE are cancer procoagulant (CP) and TF [5]. The gene discussed is TF; the disease is cancer.